




Therapy

Compound for treating proteopathies or conformational disorders and a diagnostic protocol

A research group from the Andalusian Public Health System (SSPA) has developed a compound for the treatment of proteopathies or conformational disorders. In turn, the group is also proposing a diagnostic protocol for such diseases.



Description



Intellectual Property

Parkinson's and Alzheimer's are two of the most common proteopathies or conformational disorders, and most prevalent in industrialised countries.

This technology is protected by patent.

In recent years, immunisation has been proposed as a therapeutic strategy for the treatment of certain neurodegenerative proteopathies. This pathway has not been studied adequately in the context of Parkinson's, and together with other techniques, none have proved optimal in the management of such diseases.



Aims

The researchers have developed a compound for treating neurodegenerative conformational disorders, such as Parkinson's. In addition, they are proposing a diagnostic protocol for detecting specific features of this disease, so as to then be in a better position to apply the most appropriate treatment and management pathway.

We are looking for a partner interested in a license and/or a collaboration agreement to further develop and exploit this innovative technology.



Classification

Studies conducted on mice have demonstrated its protective and preventive effects in terms of the symptoms associated with these disorders, such as Parkinson's.

Area: Biotech-Pharma (Therapy)
Technology: Vaccine
Pathology: Central Nervous System



Advantages

Its advantages are the development of a kit for detecting neurodegenerative disorders, such as Parkinson's, to potentially help address and/or monitor the condition. In addition, the proposed compound offers an immunisation mechanism against these proteopathies.